학술논문
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Document Type
Article
Author
Costa Clemens, Sue Ann; Weckx, Lily; Clemens, Ralf; Almeida Mendes, Ana Verena; Ramos Souza, Alessandra; Silveira, Mariana B V; da Guarda, Suzete Nascimento Farias; de Nobrega, Maristela Miyamoto; de Moraes Pinto, Maria Isabel; Gonzalez, Isabela G S; Salvador, Natalia; Franco, Marilia Miranda; de Avila Mendonça, Renata Navis; Queiroz Oliveira, Isabelle Silva; de Freitas Souza, Bruno Solano; Fraga, Mayara; Aley, Parvinder; Bibi, Sagida; Cantrell, Liberty; Dejnirattisai, Wanwisa; Liu, Xinxue; Mongkolsapaya, Juthathip; Supasa, Piyada; Screaton, Gavin R; Lambe, Teresa; Voysey, Merryn; Pollard, Andrew J; Bittaye, Mustapha; Woods, Danielle; Davies, Sophie; Smith, Holly; Ulaszewska, Marta; Sanders, Helen; Mabette, Reece; Vernon, Sophie; Valliji, Zara; Mead, Gracie; Tejpal, Chitra; Park, Juyeon; Beveridge, Amy; Eldawi, Ahmed; Felle, Sally; Fraga, Mayara; Muniz Martins, Thaiane; Martins Medrado, Claudia Loureiro; de Arruda Cordeiro Matos, Laiana Januse
Source
The Lancet; February 2022, Vol. 399 Issue: 10324 p521-529, 9p
Subject
Language
ISSN
01406736; 1474547X
Abstract
The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses.